Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CARE

Financiado

Cerrado

Corona Accelerated R D in Europe

The Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) pandemic has emerged as the largest global health threat to humanity in this century. According to the World Health Organisation Situation Report of March 28th 2020,... ver más

31/03/2025

INSERM

76M€

Presupuesto del proyecto: 76M€

Líder del proyecto

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 44 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-08-07

IMI2-2020-21-01: Development of therapeutics and dia...

I+D

Cerrada hace 4 años

0% 48% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

44 Participantes

INSERM

7.51M€ | Lider

ACCIONA CONSTRUCCION

7.73M€ | Participante

IKTOS

391.50K€ | Participante

UNIWERSYTET JAGIELLONSKI

301.10K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PID2021-127496NB-I00 ANALISIS DE LAS BASES MOLECULARES DE LA INTERACCION SARS-COV... 133K€ Cerrado

MAD-CoV 2 Modern approaches for developing antivirals against SARS CoV... 6M€ Cerrado

SCORE Swift COronavirus therapeutics REsponse 3M€ Cerrado

NAVIPP New AntiVirals for Infections with Pandemic Potential 6M€ Cerrado

CENTRO DE DIAGNÓSTICO E INVESTIGACIÓN VÍRICO... CENTRO DE DIAGNÓSTICO E INVESTIGACIÓN VÍRICO PARA EL SARS CO... 179K€ Cerrado

COVID-19 VACCINES PROPOSAL FOR FUNDING RESEARCH DEVELOPMENT AND MANUFACTURING... 150M€ Cerrado

Duración del proyecto: 55 meses Fecha Inicio: 2020-08-07
Fecha Fin: 2025-03-31

Líder del proyecto

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 76M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) pandemic has emerged as the largest global health threat to humanity in this century. According to the World Health Organisation Situation Report of March 28th 2020, 571,659 patients were diagnosed with Coronavirus Disease 2019 (COVID-19) and 26,493 deaths were reported globally. The wide spectrum of clinical symptoms, disease severity in high risk individuals, transmission efficiency and high mortality, raises an immediate need for vaccines or therapeutics. Given that the viral variant is new in the human population and emerged less than 4 months ago, there is no vaccine or approved therapies. The Corona Accelerated R&D in Europe (CARE) consortium is a coalition of 37 globally renowned academic institutions, pharmaceutical companies and non-profit research organizations who have committed to rapidly and efficiently address this emergent health threat, and the main objectives are: the development of therapeutics (i) to provide an emergency response towards the current COVID-19 pandemic by drug repositioning and (ii) to address the current and/or future coronavirus outbreaks by broad-spectrum small-molecule drug discovery and/or virus-neutralizing antibody discovery. To achieve this, a collection of repurposed drugs, focused libraries and small molecule libraries will be screened against SARS-CoV-2, other emerging SARS-CoV-2 clades and related coronavirus genera in phenotypic or target-based assays. A focused medicinal chemistry campaign will identify small-molecule hits, and Absorption, Distribution, Metabolism and Excretion (ADME), pharmacokinetic/pharmacodynamic (PK/PD), potency and safety of these therapeutic candidates will be assessed in vitro and in animal models. Virus-neutralizing monoclonal antibodies will be generated and further characterized. Immune markers will be identified contributing to the host immune responses to SARS-CoV-2 infections, and the correlation with clinical and virological outcomes will be determined. Finally, lead candidates will be advanced into Phase1 and Phase 2 clinical trials in humans. With this reactive response, the CARE consortium is dedicated to win the fight against coronavirus.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores